Journal of Internal Medicine 2005; **257**: 571–575

Author index

Abate, G. *see* Neri, S.
Adams, K.T. *see* Pacak, K.
Akiyama, N. *see* Sato, N.
Alfthan, G. *see* Virtanen, J.K.
Alikasifoglu, M. *see* Tutuncu, N.B.
Almgren, T., Persson, B., Wilhelmsen, L., Rosengren, A. & Andersson, O.K. Stroke and coronary heart disease in treated hypertension – a prospective cohort study over three decades, 496
Altavilla, G. *see* Gianni, S.
Anaya, J.-M. *see* Ramos-Casals, M.
Andersson, J. The inflammatory reflex – Introduction, 122
Andersson, O.K. *see* Almgren, T.
Andreasen, F. *see* Rejnmark, L.
Andronico, G. *see* Mulè, G.
Angelin, B. *see* Eriksson, M.
Asano, A. *see* Murase, Y.

Bachli, E.B. *see* Chopard, P.
Baldan, A. *see* Gianni, S.
Bång, A. *see* Hollenberg, J.
Beltran, E. *see* Böhm, F.
Berger, D. *see* Kagansky, N.
Berglund, G. *see* Rosvall, M.
Berglund, G. *see* Wallström, P.
Bernabeu-Wittel, M. *see* García-Morillo, J.S.
Bertazzo, M. *see* Gianni, S.
Berthold, H.K. *see* Gouni-Berthold, I.
Bets, D. *see* De Jager, J.
Bézie, Y. *see* Rajzbaum, G.
Bigazzi, F. *see* Sampietro, T.
Bilezikian, J.P., Brandi, M.L., Rubin, M. & Silverberg, S.J. Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features, 6
Bilo, H.J.G. *see* Diepeveen, S.H.A.
Bionda, A. *see* Sampietro, T.
Blacher, J. *see* Rajzbaum, G.
Blalock, J.E. The immune system as the sixth sense, 126
Boekhout, T. *see* Lagrou, K.
de Boer, M.-J. *see* Timmer, J.R.
Böhm, F., Beltran, E. & Pernow, J. Endothelin receptor blockade improves endothelial function in atherosclerotic patients on angiotensin converting enzyme inhibition, 263
Bounameaux, H. *see* Chopard, P.
Bradley, K.J., Hobbs, M.R., Buley, I.D., Carpten, J.D., Cavaco, B.M., Fares, J.E., Laidler, P., Manek, S., Robbins, C.M., Salti, I.S., Thompson, N.W., Jackson, C.E. & Thakker, R.V. Uterine tumours are a phenotypic manifestation of the hyperparathyroidism-jaw tumour syndrome, 18
Brandi, M.L. *see* Bilezikian, J.P.
Brandi, M.L. *see* Tonelli, F.
Brauckhoff, M. *see* Machens, A.
Brégeon, F. *see* Jammes, Y.
Bréville, P. *see* Rajzbaum, G.
Buley, I.D. *see* Bradley, K.J.
Burger, W., Chemnitius, J.-M., Kneissl, G.D. & Rücker, G. Low-dose aspirin for secondary cardiovascular prevention–cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation – review and meta-analysis, 399

du Cailar, G. *see* Mourad, J.-J.
Calvo-Alen, J. *see* Ramos-Casals, M.
Campanile, E. *see* Neri, S.
Canova, C.R. *see* Chopard, P.
Carling, T. & Udelsman, R. Parathyroid surgery in familial hyperparathyroid disorders, 27
Carlsson, S., Persson Brobert, G.P. & Grill, V. Influence of smoking and snus on the prevalence and incidence of type 2 diabetes amongst men: the northern Sweden MONICA study, 481
Carneado de la Fuente, J. *see* García-Morillo, J.S.
Carpten, J.D. *see* Bradley, K.J.
Cavaco, B.M. *see* Bradley, K.J.
Cecchetto, A. *see* Gianni, S.
Cerasola, G. *see* Mulè, G.
Cermakova, Z. *see* Petrkova, J.
Chauffert, M. *see* Rajzbaum, G.
Chella, E. *see* Sampietro, T.
Chemnitius, J.-M. *see* Burger, W.
Chen, C.-H. *see* Chen, H.-A.
Chen, H.-A., Cheng, N.-C., Lin, K.-P., Liao, H.-T., Chen, C.-H. & Huang, D.-F. Mononeuropathy multiplex and chylothorax as earlier manifestations of pulmonary tuberculosis, 561
Cheng, N.-C. *see* Chen, H.-A.
Chiasson, J.-L. *see* Zacharova, J.
Chopard, P., Dörffler-Melly, J., Hess, U., Wuillemin, W.A., Hayoz, D., Gallino, A., Bachli, E.B., Canova, C.R., Isenegger, J., Rubino, R. & Bounameaux, H. Venous thromboembolism prophylaxis in acutely ill medical patients: definite need for improvement, 352
Cilio, D. *see* Neri, S.
Coco, A. *see* Menzaghi, C.
Cottone, S. *see* Mulè, G.
Crook, M.A. & Panteli, J.V. The refeeding syndrome and hypophosphataemia in the elderly, 397
Cusimano, P. *see* Mulè, G.
Czura, C.J. & Tracey, K.J. Autonomic neural regulation of immunity, 156

Dahlbäck, B. Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases, 209
Dal Pino, B. *see* Sampietro, T.
De Giorgio, M. *see* Gianni, S.
De Jager, J., Kooy, A., Lehert, P.H., Bets, D., Wulffelé, M.G., Teerlink, T., Scheffer, P.G., Schalkwijk, C.G., Donker, A.J.M. & Stehouwer, C.D.A. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial, 100
Deferrari, G. *see* Leoncini, G.
Delliaux, S. *see* Jammes, Y.
Di Paola, R. *see* Menzaghi, C.
Di Pino, L. *see* Neri, S.
Di Prima, P. *see* Neri, S.
Diepeveen, S.H.A., Verhoeven, G.W.H.E., van der Palen, J., Dikkeschei, L.D., van Tits, L.J., Kolsters, G., Offerman, J.J.G., Bilo, H.J.G. & Stalenhoef, A.F.H. Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial, 438
Dikkeschei, L.D. *see* Diepeveen, S.H.A.
Dimmeler, S. *see* Lundberg, G.A.
Donker, A.J.M. *see* De Jager, J.
Dörffler-Melly, J. *see* Chopard, P.
Doria, A. *see* Menzaghi, C.
Dralle, H. *see* Machens, A.
Drøyvold, W.B., Lund Nilsen, T.I., Lydersen, S., Midthjell, K., Nilsson, P.M., Nilsson, J.-Å. & Holmen, J. Weight change and mortality: the Nord-Trøndelag Health Study, 338

Egami, Y. *see* Sakai, Y.
Eggertsen, G. *see* Harper, P.

© 2005 Blackwell Publishing Ltd

Eisenhofer, G. *see* Pacak, K.
Eliasson, M., Nasic, S. & Rodu, B. In reply to 'Influence of smoking and snus on the prevalence and incidence of type 2 diabetes amongst men: the northern Sweden MONICA', 483
Engström, G. *see* Rosvall, M.
Erbas, T. *see* Tutuncu, N.B.
Ercolino, T. *see* Menzaghi, C.
Erhardt, L. *see* Herlitz, J.
Eriksson, M., Angelin, B. & Sjöberg, S. Risk for fatal statin-induced rhabdomyolysis as a consequence of misinterpretation of 'evidence-based medicine', 313
Eriksson, P. *see* Lundberg, G.A.
Eriksson, P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab, 540

Fagiuoli, S. *see* Gianni, S.
Falchetti, A. *see* Tonelli, F.
Falqui, V. *see* Leoncini, G.
Fares, J.E. *see* Bradley, K.J.
Farinati, F. *see* Gianni, S.
Faust, M. *see* Gouni-Berthold, I.
Fehm, H.L. *see* Oltmanns, K.M.
Fini, G. *see* Menzaghi, C.
Floderus, Y. *see* Harper, P.
Font for the Hispamec study group, J. *see* Ramos-Casals, M.
Frandsen, E. *see* Melander, O.
Franken, A.A.M. *see* Wolffenbuttel, B.H.R.
Fratini, G. *see* Tonelli, F.
Frostegård, J. SLE, atherosclerosis and cardiovascular disease, 485

Gåfvels, M. *see* Harper, P.
Gallino, A. *see* Chopard, P.
García-Morillo, J.S., Ramírez Lorca, R., Bernabeu-Wittel, M., Stiefel García-Junco, P., Pamies Andreu, E. & Carneado de la Fuente, J. Iron status and *HFE* mutations in first-degree relatives of patients with sporadic porphyria cutanea tarda, in a Mediterranean area, 389
García-Morillo, J.S., Ramírez Lorca, R., Bernabeu-Wittel, M., Stiefel García-Junco, P., Pamies Andreu, E. & Carneado de la Fuente, J. Response to Harper *et al.*, 392
Giannakidou, E. *see* Gouni-Berthold, I.
Gianni, S., Cecchetto, A., Altavilla, G., Ragazzi, R., Bertazzo, M., De Giorgio, M., Baldan, A., Fagiuoli, S. & Farinati, F. Tumour staging, morphology and p53 overexpression concur in predicting survival in hepatocellular carcinoma, 367
Gimm, O. *see* Machens, A.
Giustolisi, N. *see* Neri, S.
Gøtzsche, P.C. *see* Hróbjartsson, A.
Gouni-Berthold, I., Giannakidou, E., Müller-Wieland, D., Faust, M., Kotzka, J., Berthold, H.K. & Krone, W. The Pro387Leu variant of protein tyrosine phosphatase-1B is not associated with diabetes mellitus type 2 in a German population, 272
Grill, V. *see* Carlsson, S.
Groop, L. *see* Melander, O.
Grubb, A. *see* Melander, O.

Hagen, F. *see* Lagrou, K.
Haglid Evander, M. *see* Herlitz, J.
Hamsten, A. *see* Lundberg, G.A.
Hansson, G.K. *see* Lundberg, G.A.
Harper, P., Floderus, Y., Holmström, P., Eggertsen, G. & Gåfvels, M. Response to García-Morillo *et al.*, 391
Harper, P., Floderus, Y., Holmström, P., Eggertsen, G. & Gåfvels, M. Response to García-Morillo *et al.*, 393
Hayoz, D. *see* Chopard, P.
Hedblad, B. *see* Rosvall, M.
Heickendorff, L. *see* Rejnmark, L.
Herlitz, J., Holm, J., Peterson, M., Karlson, B.W., Haglid Evander, M. & Erhardt, L. for the Lowasa study group. Factors associated with development of stroke long-term after myocardial infarction: experiences from the LoWASA trial, 201
Herlitz, J. *see* Hollenberg, J.
Hess, U. *see* Chopard, P.
Hijii, C. *see* Sakai, Y.
Hobbs, M.R. *see* Bradley, K.J.
van't Hof, A.W.J. *see* Timmer, J.R.
Hollenberg, J., Bång, A., Lindqvist, J., Herlitz, J., Nordlander, R., Svensson, L. & Rosenqvist, M. Difference in survival after out-of-hospital cardiac arrest between the two largest cities in Sweden: a matter of time?, 247
Holm, J. *see* Herlitz, J.
Holmen, J. *see* Drøyvold, W.B.
Holmström, P. *see* Harper, P.
Hoorntje, J.C.A. *see* Timmer, J.R.
Höppener, J.W. *see* Lips, C.J.
Hróbjartsson, A. & Gøtzsche, P.C. Response to Meissner: our preference of patient-reported to observer-reported outcomes has trivial influence on our updated systematic review of the effect of placebo, 395
Huang, D.-F. *see* Chen, H.-A.
Hvas, A.-M. & Nexo, E. Holotranscobalamin – a first choice assay for diagnosing early vitamin B_{12} deficiency?, 289

Iglseder, B. *see* Strohmer, B.
Ilias, I. *see* Pacak, K.
Isenegger, J. *see* Chopard, P.
Ito, H. *see* Sakai, Y.

Jackson, C.E. *see* Bradley, K.J.
Jammes, Y., Steinberg, J.G., Mambrini, O., Brégeon, F. & Delliaux, S. Chronic fatigue syndrome: assessment of increased oxidative stress and altered muscle excitability in response to incremental exercise, 299
Janzon, L. *see* Rosvall, M.
Janzon, L. *see* Wallström, P.
Jara, L.-J. *see* Ramos-Casals, M.
Jingu, S. *see* Sakai, Y.
Jolobe, O.M.P. Diagnosing heart failure in aortic valve stenosis, 484
Jovinge, S. *see* Melander, O.
Justad, G. *see* Lappegård, K.T.

Kagansky, N., Levy, S., Koren-Morag, N., Berger, D. & Knobler, H. Hypophosphataemia in old patients is associated with the refeeding syndrome and reduced survival, 461
Kahan, T. *see* Nyström, F.
Kamata, T. *see* Sato, N.
Kanda, T. *see* Sato, N.
Kaplan, G.A. *see* Virtanen, J.K.
Karlson, B.W. *see* Herlitz, J.
Kellin, A. *see* Lundberg, G.A.
Keuleers, S. *see* Lagrou, K.
Klein, H.G. Pathogen inactivation technology: cleansing the blood supply, 224
Kneissl, G.D. *see* Burger, W.
Knobler, H. *see* Kagansky, N.
Kobayashi, J. *see* Murase, Y.
Kolsters, G. *see* Diepeveen, S.H.A.
Kooy, A. *see* De Jager, J.
Koren-Morag, N. *see* Kagansky, N.
Korhonen, M.J. *see* Virtanen, J.K.
Kotzka, J. *see* Gouni-Berthold, I.
Krone, W. *see* Gouni-Berthold, I.
Kuwana, M. *see* Sato, N.

Laakso, M. *see* Zacharova, J.
Lagrou, K., Van Eldere, J., Keuleers, S., Hagen, F., Merckx, R., Verhaegen, J., Peetermans, W.E. & Boekhout, T. Zoonotic transmission of *Cryptococcus neoformans* from a magpie to an immunocompetent patient. 385
Laidler, P.H. *see* Bradley, K.J.
Lappegård, K.T., Justad, G., Prytz, J.F. & Manhenke, C. Thoracic myelitis as a possible cause of myocardial infarction. 558
Lehert, P. *see* De Jager, J.
Leoncini, G., Ratto, E., Viazzi, F., Vaccaro, V., Parodi, D., Parodi, A., Falqui, V., Tomolillo, C., Deferrari, G. & Pontremoli, R. Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients. 454
Levy, S. *see* Kagansky, N.
Liao, H.-T. *see* Chen, H.-A.
Lin, K.-P. *see* Chen, H.-A.
Lind, L. *see* Nyström, F.
Lindqvist, J. *see* Hollenberg, J.
Lip, G.Y.H. *see* Tayebjee, M.H.
Lips, C.J., Höppener, J.W., Van Nesselrooij, B.P. & Van der Luijt, R.B. Counselling in multiple endocrine neoplasia syndromes: from individual experience to general guidelines. 69
Lukl, J. *see* Petrkova, J.
Lund Nilsen, T.I. *see* Drøyvold, W.B.
Lundberg, G.A., Kellin, A., Samnegård, A., Lundman, P., Tornvall, P., Dimmeler, S., Zeiher, A.M., Hamsten, A., Hansson, G.K. & Eriksson, P. Severity of coronary artery stenosis is associated with a polymorphism in the CXCL16/SR-PSOX gene. 415
Lundman, P. *see* Lundberg, G.A.
Lydersen, S. *see* Drøyvold, W.B.

Mabuchi, H. *see* Murase, Y.
MacFadyen, R.J. *see* Tayebjee, M.H.
Machens, A., Ukkat, J., Brauckhoff, M., Gimm, O. & Dralle, H. Advances in the management of hereditary medullary thyroid cancer. 50
Magnusson, M. *see* Melander, O.
Maier, S.F. *see* Watkins, L.R.
Malmqvist, K. *see* Nyström, F.
Mambrini, O. *see* Jammes, Y.
Mañá, J. *see* Ramos-Casals, M.
Manek, S. *see* Bradley, K.J.
Manhenke, C. *see* Lappegård, K.T.
Marx, S.J. & Stratakis, C.A. Multiple endocrine neoplasia – Introduction. 2
Mattisson, I. *see* Wallström, P.
Mauceri, B. *see* Neri, S.
Medina, F. *see* Ramos-Casals, M.
Meissner, K. Preferring patient-reported to observer-reported outcomes substantially influences the results of the updated systematic review on placebos by Hróbjartsson and Gøtzsche. 394
Melander, O., Frandsen, E., Magnusson, M., Grubb, A., Jovinge, S. & Groop, L. Nt-proANP in plasma, a marker of salt sensitivity, is reduced in type 2 diabetes patients. 281
Menzaghi, C., Ercolino, T., Salvemini, L., Coco, A., Fini, G., Di Paola, R., Doria, A. & Trischitta, V. Lack of evidence for interaction between APM1 and PPARγ2 genes in modulating insulin sensitivity in nondiabetic Caucasians from Italy. 315
Merckx, R. *see* Lagrou, K.
Meyer-Hoffert, U. *see* Wiedow, O.
Mezzatesta, G. *see* Mulè, G.
Midthjell, K. *see* Drøyvold, W.B.
Mimran, A. *see* Mourad, J.-J.
Misseri, M. *see* Neri, S.
Mondati, E. *see* Neri, S.
Mongiovì, R. *see* Mulè, G.
Mosekilde, L. *see* Rejnmark, L.
Mosekilde, L. *see* Vestergaard, P.
Mourad, J.-J., du Cailar, G., Nazal, E.-M., Safar, M.E. & Mimran, A. Age-related increase of pulse pressure and plasminogen activator inhibitor-1 I/D gene polymorphism in essential hypertension. 93
Mulè, G., Nardi, E., Cottone, S., Cusimano, P., Volpe, V., Piazza, G., Mongiovì, R., Mezzatesta, G., Andronico, G. & Cerasola, G. Influence of metabolic syndrome on hypertension-related target organ damage. 503
Müller-Wieland, D. *see* Gouni-Berthold, I.
Murase, Y., Asano, A., Kobayashi, J., Yamaaki, N. & Mabuchi, H. Impact of adiposity on carotid atherosclerosis in Japanese males with metabolic syndrome. 311
Mursu, J. *see* Virtanen, J.K.

Nardi, E. *see* Mulè, G.
Nasic, S. *see* Eliasson, M.
Nazal, E.-M. *see* Mourad, J.-J.
Neri, S., Signorelli, S.S., Mondati, E., Pulvirenti, D., Campanile, E., Di Pino, L., Scuderi, M., Giustolisi, N., Di Prima, P., Mauceri, B., Abate, G., Cilio, D., Misseri, M. & Scuderi, R. Ultrasound imaging in diagnosis of superior mesenteric artery syndrome. 346
Nesi, G. *see* Tonelli, F.
Nexo, E. *see* Hvas, A.-M.
Nilsson, J.-Å. *see* Drøyvold, W.B.
Nilsson, P.M. *see* Drøyvold, W.B.
Nord, C.E. *see* Sullivan, Å.
Nordlander, R. *see* Hollenberg, J.
Numan, S.C. *see* Van Dissel, J.T.
Nyström, F., Malmqvist, K., Lind, L. & Kahan, T. Nurse-recorded clinic and ambulatory blood pressures correlate equally well with left ventricular mass and carotid intima-media thickness. 514

Offerman, J.J.G. *see* Diepeveen, S.H.A.
Ohoto, N. *see* Sakai, Y.
Oltmanns, K.M., Fehm, H.L. & Peters, A. Chronic fentanyl application induces adrenocortical insufficiency. 478
Ottervanger, J.P. *see* Timmer, J.R.

Pacak, K., Ilias, I., Adams, K.T. & Eisenhofer, G. Biochemical diagnosis, localization and management of pheochromocytoma: focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour. 60
van der Palen, J. *see* Diepeveen, S.H.A.
Pamies Andreu, E. *see* García-Morillo, J.S.
Panteli, J.V. *see* Crook, M.A.
Parodi, A. *see* Leoncini, G.
Parodi, D. *see* Leoncini, G.
Paulweber, B. *see* Strohmer, B.
Peetermans, W.E. *see* Lagrou, K.
Pernow, J. *see* Böhm, F.
Persson Brobert, G.P. *see* Carlsson, S.
Persson, B. *see* Almgren, T.
Peters, A. *see* Oltmanns, K.M.
Peterson, M. *see* Herlitz, J.
Petrek, M. *see* Petrkova, J.
Petrkova, J., Cermakova, Z., Lukl, J. & Petrek, M. CC chemokine receptor 5 (CCR5) deletion polymorphism does not protect Czech males against early myocardial infarction. 564
Piazza, G. *see* Mulè, G.
Pichler, M. *see* Strohmer, B.

Pontremoli, R. *see* Leoncini, G.
Prytz, J.F. *see* Lappegård, K.T.
Pulvirenti, D. *see* Neri, S.
Puntoni, M.R. *see* Sampietro, T.

Ragazzi, R. *see* Gianni, S.
Rajzbaum, G., Roger, V.L., Bézie, Y., Chauffert, M., Bréville, P., Roux, F., Safar, M.E. & Blacher, J. French women, fractures and aortic calcifications, 117
Ramírez Lorca, R. *see* García-Morillo, J.S.
Ramos-Casals, M., Jara, L.-J., Medina, F., Rosas, J., Calvo-Alen, J., Mañá, J., Anaya, J.-M. & Font for the Hispamec study group, J. Systemic autoimmune diseases co-existing with chronic hepatitis C virus infection (the HISPAMEC Registry): patterns of clinical and immunological expression in 180 cases, 549
Ratto, E. *see* Leoncini, G.
Rejnmark, L., Vestergaard, P., Heickendorff, L., Andreasen, F. & Mosekilde, L. Effects of long-term treatment with loop diuretics on bone mineral density, calcitropic hormones and bone turnover, 176
Rejnmark, L. *see* Vestergaard, P.
Rissanen, T.H. *see* Virtanen, J.K.
Rizzetto, M. *see* Sansoè, G.
Robbins, C.M. *see* Bradley, K.J.
Rodu, B. *see* Eliasson, M.
Roger, V.L. *see* Rajzbaum, G.
Rosas, J. *see* Ramos-Casals, M.
Rosengren, A. *see* Almgren, T.
Rosenqvist, M. *see* Hollenberg, J.
Rosina, F. *see* Sansoè, G.
Rossi, G. *see* Sampietro, T.
Rosvall, M., Janzon, L., Berglund, G., Engström, G. & Hedblad, B. Incident coronary events and case fatality in relation to common carotid intima-media thickness , 430
Roux, F. *see* Rajzbaum, G.
Rubin, M. *see* Bilezikian, J.P.
Rubino, R. *see* Chopard, P.
Rücker, G. *see* Burger, W.

Safar, M.E. *see* Mourad, J.-J.
Safar, M.E. *see* Rajzbaum, G.
Sakai, Y., Ito, H., Egami, Y., Ohoto, N., Hijii, C., Yanagawa, M., Satoh, S. & Jingu, S. Favourable association of leg fat with cardiovascular risk factors, 194
Salonen, J.T. *see* Virtanen, J.K.
Salti, I.S. *see* Bradley, K.J.
Salvemini, L. *see* Menzaghi, C.
Samnegård, A. *see* Lundberg, G.A.
Sampietro, T., Bigazzi, F., Rossi, G., Dal Pino, B., Puntoni, M.R., Sbrana, F., Chella, E. & Bionda, A. Upregulation of the immune system in primary hypercholesterolaemia: effect of atorvastatin therapy, 523
Sansoè, G., Silvano, S., Rosina, F., Smedile, A. & Rizzetto, M. Evidence of a dynamic aldosterone-independent distal tubular control of renal sodium excretion in compensated liver cirrhosis, 358
Sato, N., Kamata, T., Akiyama, N., Kuwana, M. & Kanda, T. Acute inflammatory sensorimotor polyradiculoneuropathy associated with immune thrombocytopenic purpura, 473
Satoh, S. *see* Sakai, Y.
Sbrana, F. *see* Sampietro, T.
Schalkwijk, C.G. *see* De Jager, J.
Scheffer, P.G. *see* De Jager, J.
Scherer, P.E. *see* Trujillo, M.E.
Scuderi, M. *see* Neri, S.
Scuderi, R. *see* Neri, S.
Signorelli, S.S. *see* Neri, S.
Silvano, S. *see* Sansoè, G.
Silverberg, S.J. *see* Bilezikian, J.P.
Sjöberg, S. *see* Eriksson, M.
Smedile, A. *see* Sansoè, G.
Stalenhoef, A.F.H. *see* Diepeveen, S.H.A.
Stehouwer, C.D.A. *see* De Jager, J.
Steinberg, J.G. *see* Jammes, Y.
Stiefel García-Junco, P. *see* García-Morillo, J.S.
Stratakis, C.A. *see* Marx, S.J.
Strohmer, B., Pichler, M., Iglseder, B. & Paulweber, B. Relationship of QT interval duration with carotid intima media thickness in a clinically healthy population undergoing cardiovascular risk screening, 238
Sullivan, Å. & Nord, C.E. Probiotics and gastrointestinal diseases, 78
Suryapranata, H. *see* Timmer, J.R.
Svensson, L. *see* Hollenberg, J.

Tan, K.T. *see* Tayebjee, M.H.
Tayebjee, M.H., Tan, K.T., MacFadyen, R.J. & Lip, G.Y.H. Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: relationship to disease severity, 110
Teerlink, T. *see* De Jager, J.
Thakker, R.V. *see* Bradley, K.J.
Thompson, N.W. *see* Bradley, K.J.
Timmer, J.R., Ottervanger, J.P., Hoorntje, J.C.A., de Boer, M.-J., Suryapranata, H., van't Hof, A.W.J. & Zijlstra, F. on behalf of the Zwolle Myocardial Infraction study group. Prognostic value of erythrocyte sedimentation rate in ST segment elevation myocardial infarction: interaction with hyperglycaemia, 423
van Tits, L.J. *see* Diepeveen, S.H.A.
Todorova, B.R. *see* Zacharova, J.
Tomolillo, C. *see* Leoncini, G.
Tonelli, F., Fratini, G., Falchetti, A., Nesi, G. & Brandi, M.L. Surgery for gastroenteropancreatic tumours in multiple endocrine neoplasia type 1: review and personal experience, 38
Tornvall, P. *see* Lundberg, G.A.
Tracey, K.J. *see* Czura, C.J.
Trischitta, V. *see* Menzaghi, C.
Trujillo, M.E. & Scherer, P.E. Adiponectin – journey from an adipocyte secretory protein to biomarker of the metabolic syndrome, 167
Tuncbilek, E. *see* Tutuncu, N.B.
Tutuncu, N.B., Erbas, T., Alikasifoglu, M. & Tuncbilek, E. Thermolabile methylenetetrahydrofolate reductase enzyme genotype is frequent in type 2 diabetic patients with normal fasting homocysteine levels, 446
Tydén, P. *see* Wallström, P.

Udelsman, R. *see* Carling, T.
Ukkat, J. *see* Machens, A.

Vaccaro, V. *see* Leoncini, G.
Van der Luijt, R.B. *see* Lips, C.J.
Van Dissel, J.T., Numan, S.C. & van't Wout, J.W. Chills in 'early sepsis': good for you?, 469
Van Eldere, J. *see* Lagrou, K.
Van Nesselrooij, B.P. *see* Lips, C.J.
Verhaegen, J. *see* Lagrou, K.
Verhoeven, G.W.H.E. *see* Diepeveen, S.H.A.
Vestergaard, P., Rejnmark, L. & Mosekilde, L. Fracture risk associated with systemic and topical corticosteroids, 374
Vestergaard, P. *see* Rejnmark, L.
Viazzi, F. *see* Leoncini, G.
Vincent on behalf of the Dutch Corall study group, H.H. *see* Wolffenbuttel, B.H.R.

Virtanen, J.K., Voutilainen, S., Aifthan, G., Korhonen, M.J., Rissanen, T.H., Mursu, J., Kaplan, G.A. & Salonen, J.T. Homocysteine as a risk factor for CVD mortality in men with other CVD risk factors: the Kuopio Ischaemic Heart Disease Risk Factor (KIHD) Study, 255
Volpe, V. *see* Mulè, G.
Voutilainen, S. *see* Virtanen, J.K.

Wallström, P., Mattisson, I., Tydén, P., Berglund, G. & Janzon, L. Dietary habits after myocardial infarction – results from a cross-sectional study, 329
Watkins, L.R. & Maier, S.F. Immune regulation of central nervous system functions: from sickness responses to pathological pain, 139
Wiedow, O. & Meyer-Hoffert, U. Neutrophil serine proteases: potential key regulators of cell signalling during inflammation, 319
Wilhelmsen, L. *see* Almgren, T.
Wolffenbuttel, B.H.R., Franken, A.A.M. & Vincent on behalf of the Dutch Corall study group, H.H. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes – CORALL study, 531
van't Wout, J.W. *see* Van Dissel, J.T.
Wuillemin, W.A. *see* Chopard, P.
Wulffelé, M.G. *see* De Jager, J.

Yamaaki, N. *see* Murase, Y.
Yanagawa, M. *see* Sakai, Y.

Zacharova, J., Todorova, B.R., Chiasson, J.-L. & Laakso, M. The G-250A substitution in the promoter region of the hepatic lipase gene is associated with the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial, 185
Zeiher, A.M. *see* Lundberg, G.A.
Zijlstra, F. *see* Timmer, J.R.

Keyword index

abdominal pain, 346
acetylcholine, 156
ACRP30, 167
acute inflammatory polyneuropathy, 473
acute myocardial infarction, 201
adhesion molecules, 523
adrenocortical insufficiency, 478
adverse event, 399
ageing, 93
age-related progression, 50
aldosterone, 358
allodynia, 139
ambulatory blood pressure, 514
anti-ganglioside antibody, 473
anti-GD1b antibody, 473
anti-neutrophil cytoplasmic antibody, 540
antiphospholipid antibodies, 485
antiphospholipid syndrome, 549
aorto-mesenteric angle, 346
APC resistance, 209
apolipoproteins, 531
Asians, 194
aspirin, 399
atherosclerosis, 167, 238, 415, 430, 485, 523
atorvastatin, 523, 531
audit of practice, 352

biochemical bone markers, 176
biological neoplastic markers, 367
bleeding complication, 399
blood safety, 224
body composition, 329
body mass index, 338
bone density, 6
bone mineral density, 176
bone tumours, 18
bystander CPR, 247

calcitonin monitoring, 50
cardiac arrest, 247
cardiac repolarization, 238
cardiology, 263
cardiovascular disease, 255, 558
cardiovascular prevention, 399
Carney Complex, 2
carotid arteries, 430
carotid artery, 514
cathepsin G, 319
chemokine, 415
chills, 469
cholesterol, 496
chronic fatigue syndrome, 299
chylothorax, 561
clinical physiology, 263
clinical trial, 100
complement, 523
computerized tomography, 60
coronary event, 430
coronary risk factor, 194
corticosteroid, 374
counselling in multiple endocrine neoplasia, 69
cross-sectional studies, 329
Cryptococcus neoformans, 385
CXCL16, 415
cyclic AMP, 2
cytokine, 122
cytokines, 156, 319, 469

diabetes, 100
diabetes mellitus, 446
diabetes mellitus type 2, 272
diagnostic test, 289
dialysis, 438
diarrhoea, 78
diet, 329
dopamine, 358

elastase, 319
elderly, 461
endothelial function, 100
endothelium, 263
endotoxin, 469
epidemiology, 374
erythrocyte sedimentation rate, 423
essential hypertension, 503

factor V Leiden, 209
fat distribution, 194
fracture, 374

G-250A polymorphism, 185
gastrinoma, 38
gastroenteropancreatic tumours, 38
gastrointestinal diseases, 78
genetic counselling, 2
genetic testing for multiple endocrine neoplasia, 69
genetics and familial, 27
genotyping, 272
glucose, 423
glycoprotein IIb-IIIa, 473
guidelines, 352

haemophilia, 209
hepatic lipase gene, 185
hepatitis C virus, 549
hepatocellular carcinoma, 367
holotranscobalamin, 289
homocysteine, 255, 446
HRPT2, 2
HRPT2 mutations, 18
hyperalgesia, 139
hypercalcaemia, 6
hypercholesterolaemia, 523, 531
Hyperinsulinaemia the Outcome of its Metabolic Effects, 100
hyperlipidaemia, 194
hyperparathyroid, 2
hyperparathyroidism, 27
hypertension, 93, 281, 454, 496, 514
hypophosphataemia, 461
hypo-thalamus-pituitary-adrenal axis, 478

immune neuroendocrine interactions, 126
immune thrombocytopenic purpura, 473
immuno-competence, 385
immunosensor, 126
impaired glucose tolerance, 185
incremental exercise, 299
inflammation, 122, 156, 485, 558
inflammatory reflex, 156
inhaled, 374
insulin, 100
insulin sensitivity, 167
interaction, 255
interferon alpha, 126
interleukin-1, -10, -6, 139
Internet information about multiple endocrine neoplasia, 69
intima media thickness, 238

kidney cysts, 18

left ventricular hypertrophy, 454, 503, 514
lipid, 194
lipoproteins, 438
lithium clearance, 358
liver cirrhosis, 358
loop diuretics, 176
low-grade inflammation, 100
lymphoma, 549

magnetic resonance imaging, 60
magpie, 385
matrix metalloproteinase-9, 110
medical patients, 352
medullary thyroid cancer, 50
MEN1, 2
MEN2, 2
MEN type 2, 50
metabolic response, 299
metabolic syndrome, 454, 503
metanephrines, 60
metastatic disease, 38
metformin, 100
microalbuminuria, 454, 503
middle-aged, 329
mononeuropathy multiplex, 561
multiple endocrine neoplasia, 2, 27
multiple endocrine neoplasia family alliances, 69
multiple endocrine neoplasia type 1, 38
multiple endocrine neoplasia type 2, 60
M-wave, 299
myocardial infarction, 423, 496
myocardial infarction/rehabilitation, 329

neurobiology, 558
neuro-immune modulation, 122
neuropeptides, 126
neurotransmitter receptors, 126
nodal metastasis, 50
N-terminal atrial natriuretic peptide, 281
nurse, 514
nutrition, 329

opiate, 478
osteoporosis, 176
oxidative stress, 299, 438

pain, 122, 478
Paramedics in multiple endocrine neoplasia, 69
parasympathetic, 156
parathyroid cancer, 18
parathyroid hormone, 6

© 2005 Blackwell Publishing Ltd

parathyroidectomy, 27
pathogen reduction, 224
peripheral arterial disease, 110
pheochromocytoma, 60
physical activity, 338
plaque rupture, 485
plasminogen activator inhibitor-1 gene polymorphism, 93
polyarteritis nodosa, 549
polymorphism, 415
postmenopausal women, 176
PPARγ, 167
preventive treatment in multiple endocrine neoplasia, 69
primary hyperparathyroidism, 6
PRKAR1A, 2
probiotics, 78
prognostic factors, 367
proinflammatory cytokines, 139
Pro387Leu polymorphism, 272
prospective studies, 255
protein C, 209
protein S, 209
protein tyrosine phosphatase, 272
proteinase 3, 319
PTH, 176
pulse pressure, 93

QT interval duration, 238

radionuclide imaging, 60
randomised-controlled trial, 438
receptor, 319
refeeding, 461
restenosis, 415
RET proto-oncogene, 50
rheumatoid arthritis, 549
risk factors, 255
risk stratification, 238
rituximab, 540
rosuvastatin, 531

salt sensitivity, 281
sepsis, 122, 469
Sjögren's syndrome, 549
SLE, 485
smoking, 338, 496
sodium metabolism, 358
statin, 438
STOP-NIDDM, 185
stroke, 201, 496
superior mesenteric artery syndrome, 346
surgery, 399
surgical treatment, 38
survival, 469
systemic lupus erythematosus, 549

target organ damage, 503
therapy, 540
thermolabile methylenetetrahydrofolate reductase gene, 446
thromboprophylaxis, 352
tissue inhibitor of matrix metalloproteinase-1, 110
TNF-α, 319
topical, 374
transcobalamin, 289
transfusion, 224
transmission, 385
treatment, 496
tuberculosis, 561
tumorigenesis, 2
tumour necrosis factor, 139
type 2 diabetes, 185, 281, 531

ultrasound, 346, 430
uniform guidelines on multiple endocrine neoplasia, 69
upright posture, 358

vagus, 139
vagus nerve, 156
vasculitis, 540
ventricular fibrillation, 247
vessel wall, 263
VHL, 2
virtual outpatient department for multiple endocrine neoplasia, 69
vitamin B_{12}, 289
vitamin E, 438

weight change, 338
Whipple's operation, 38
von Willebrand's disease, 209